Activated protein C resistance in Behcet's disease

被引：3

作者：

Abdel Badaee H. ^{[1
]}

Edrees A. ^{[2
]}

Amin S. ^{[3
]}

El Amir M. ^{[4
]}

Ragab G. ^{[1
]}

机构：

[1] Department of Internal Medicine, Cairo University, Cairo

[2] Department of Internal Medicine, University of Missouri-Kansas City, Kansas

[3] Department of Clinical Pathology, Cairo University, Cairo

[4] Department of Internal Medicine, Fayoum University, Fayoum

来源：

Thrombosis Journal | / 11卷 / 1期

关键词：

Homocysteine; Vascular Complication; Homocysteine Level; Hyperhomocysteinemia; Vascular Involvement;

D O I：

10.1186/1477-9560-11-17

中图分类号：

学科分类号：

摘要：

Behcet's disease is a chronic multi-system disorder of unknown etiology with protean manifestations. Venous thromboembolism is more common than arterial thrombosis, with deep vein thrombosis being the most frequent. Endothelial dysfunction resulting from vascular inflammation is considered to be an important factor of thrombosis, although the endothelial injury itself cannot completely explain the hypercoagulable state of the disease because other vasculitis syndromes do not increase the risk of thrombosis. The aim of this study is to evaluate the prevalence of activated protein C resistance (APC-R) in Egyptian patients with Behcet's disease. Also, to detect hyperhomocysteinemia in selected cases (with vascular complications) to assess their relationship with thromboembolic complications. The APC resistance ratio mean in the group of patients with vascular involvement was 2.6 ± 0.8 which was less than the group with no vascular involvement 2.8 ± 0.6, with non- significant P-value (0.5). There was more incidence of ocular lesions in the group of patients with high homocysteine level than the group of patients with normal homocytsteine level with significant P-value (0.08). © 2013 Abdel Badaee et al.; licensee BioMed Central Ltd.

引用

共 22 条

[11]

Sarican T., Ayabakan H., Turkmen S., Et al., Homocysteine: an activity marker in Behcet's disease, J Dermatol Sci, 45, pp. 121-126, (2007)

[12]

Ozkan Y., Yardim-Akaydin S., Sepici A., Et al., Assessment of homocysteine and nitric oxide levels in Behcet's disease, Clin Chem Lab Med, 45, pp. 73-77, (2007)

[13]

Lancet, 335, 8697, pp. 1078-1080, (1990)

[14]

Gurgey A., Balta G., Boyvat A., Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's disease, Blood Coagul Fibrinolysis, 14, 2, pp. 121-124, (2003)

[15]

Mammo L., Al-Dalaan A., Bahabri S.S., Saour J.N., Association of factor V Leiden with Behcet's disease, J Rheumatol, 24, pp. 2196-2198, (1997)

[16]

Navarro S., Ricart J.M., Medina P., Et al., Activated protein C levels in Behcet's disease and risk of venous thrombosis, Br J Haematol, 126, 4, pp. 550-556, (2004)

[17]

Toydemir P.B., Elhan A.H., Tukun A., Et al., Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombogenesis in Behcet's disease, J Rheumatol, 27, pp. 2849-2854, (2002)

[18]

Verity D.H., Vaughan R.W., Madanat W., Et al., Factor V Leiden mutation is associated with ocular involvement in Behcet's disease, Am J Ophthalmol, 128, pp. 352-356, (1999)

[19]

Silingardi M., Salvarani C., Boiardi L., Et al., Facror V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet's disease and deep vein thrombosis, Arthritis Rheum, 51, 2, pp. 177-183, (2004)

[20]

Aksu K., Turgan N., Oksel F., Et al., Hyperhomocysteinemia in Behcet's disease, Rheumatology, 40, 6, pp. 687-690, (2001)

← 1 2 3 →